Familial Myeloproliferative Disorders
Molecular Biology of Familial Myeloproliferative Disorders
3 other identifiers
observational
17
2 countries
6
Brief Summary
Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2008
Longer than P75 for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2008
CompletedFirst Submitted
Initial submission to the registry
April 22, 2008
CompletedFirst Posted
Study publicly available on registry
April 24, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 20, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2015
CompletedSeptember 5, 2017
September 1, 2017
6.9 years
April 22, 2008
September 1, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To determine a linkage from the DNA analyzed to find a gene that will allow for genetic evaluation of families with MPDs.
3 years
Eligibility Criteria
families with multiple member diagnosed with myeloproliferative disease
You may qualify if:
- Families with 2 or more members diagnosed with polycythemia vera (PV), essential thrombocythemia (ET), PV and ET related myelofibrosis (PV-MF and ET-MF), idiopathic myelofibrosis (IM) or chronic myelogenous leukemia (CML).
- Healthy family members of subjects diagnosed with a myeloproliferative neoplasm (MPN).
- Participating subjects must be 7 years of age or older
- A written assent, parental permission or consent must be obtained prior to any study procedures being performed.
You may not qualify if:
- Subjects who have a known acquired cause of polycythemia (increased hemoglobin/hematocrit), such as people living in high altitudes (in excess of 14,000 feet), subjects with heart disease, left to right heart shunt, severe hypoxia, cyanotic congenital heart disease, or severe pulmonary disease, will be excluded from this study, secondary forms of thrombocytosis and secondary forms of myelofibrosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Georgetown University
Washington D.C., District of Columbia, 20057, United States
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Mount Sinai School of Medicine
New York, New York, 10029, United States
Weill Cornell
New York, New York, 10065, United States
University of Utah
Salt Lake City, Utah, 84102, United States
University of Florence
Florence, Italy
Biospecimen
Blood samples from subjects and family members with myeloproliferative disease.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Josef Prachal, MD
Myeloproliferative Disorders-Research Consortium
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 22, 2008
First Posted
April 24, 2008
Study Start
March 1, 2008
Primary Completion
January 20, 2015
Study Completion
June 20, 2015
Last Updated
September 5, 2017
Record last verified: 2017-09